Processa Pharmaceuticals Inc (PCSA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.81M
Last updated: Nov 17, 2026 at 4:10 PM ET
Processa Pharmaceuticals Inc (PCSA) Stock Chart
Processa Pharmaceuticals (PCSA) has a latest price of $1.73 on Nov 17, 2026, 80.5% below its 52-week high of $8.88. Its price fell 76.9% over the past 12 months. The month-end price fell 99.3% since Oct 2017, a compound annual decline of 42.8%.
Price Chart
From Oct 2017 to Oct 2026, its highest month-end close was $9,000.00 in Dec 2019 and its lowest $1.64 in Sep 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PCSA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PCSA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 19.5%, and over 6 months it fell 33.7%. The month-end price fell 98.9% over the 3 years through Oct 2026, a compound annual decline of 77.9%.
| Period | Change |
|---|---|
| 1 month | 0.0% |
| 3 months | -19.5% |
| 6 months | -33.7% |
| 12 months | -76.9% |
| 12 months, with dividends | -76.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -98.9% | -77.9% |
| 5 years | -99.9% | -77.7% |
| Since Oct 2017 | -99.3% | -42.8% |
Price by Year
Its best calendar year was 2019, when the price rose 400.0%, and its weakest was 2025, when it fell 87.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.89 | -34.4% |
| 2025 | $2.88 | -87.0% |
| 2024 | $22.09 | -86.8% |
| 2023 | $167.30 | -69.6% |
| 2022 | $550.00 | -77.6% |
| 2021 | $2,450.00 | -25.7% |
| 2020 | $3,297.50 | -63.4% |
| 2019 | $9,000.00 | +400.0% |
Trading Range
The price is 3.6% below its 50-day average of $1.79 and 24.2% below its 200-day average of $2.28.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.73 | |
| 52-week high | $8.88 | -80.5% |
| 52-week low | $1.04 | +66.2% |
| 50-day average | $1.79 | -3.6% |
| 200-day average | $2.28 | -24.2% |
Price Risk
Over 3 years, its largest fall from a peak was 99.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.15 |
| Largest fall, 1 year | -82.4% |
| Largest fall, 3 years | -99.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PCSA
What is PCSA's 1-year price change?
Processa Pharmaceuticals's price fell 76.9% over the past 12 months. With dividends included, the 12-month total return was -76.9%.
What is PCSA's 5-year price change?
Processa Pharmaceuticals's month-end price fell 99.9% over the 5 years through Oct 2026, a compound annual decline of 77.7%. These figures leave out dividends.
What is PCSA's 52-week high and low?
Processa Pharmaceuticals's 52-week high is $8.88 and its 52-week low is $1.04. Its latest price of $1.73 on Nov 17, 2026 is 80.5% below the high.
What is PCSA's beta?
Processa Pharmaceuticals's 1-year beta against the S&P 500 is 1.15, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 82.4%.
Is the PCSA chart free?
Yes. Advanced Charting for PCSA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PCSA pages: Overview, Charting, Earnings, Financials, Statistics, Competitors